search

Active clinical trials for "Multiple Myeloma"

Results 2881-2890 of 3165

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Multiple Myeloma

This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.

Unknown status6 enrollment criteria

Diagnostic Imaging of Myeloma Bone Lesions

Multiple Myeloma

The purpose of this study is to compare the current standard whole-body x-ray with the advanced imaging techniques FDG-PET-CT, NaF-PET-CT and whole-body MRI in the detection of myeloma bone lesions.

Completed5 enrollment criteria

Imaging Young Myeloma (IMAgerie JEune Myélome)

Multiple Myeloma

Multicenter open-label prospective comparative study of PET-scan and MRI at the time of diagnosis, after 3 cycles of induction therapy (RVD) and at the completion of therapy.

Completed6 enrollment criteria

Hematopoietic Stem Cell Transplantation in Myeloma

Multiple Myeloma

The treatment assignment is based on the presence or absence of an HLA-identical sibling donor (Genetic Randomisation, NOT formal Randomisation). Patients with suitable HLA-identical sibling donors are offered a tandem transplant approach consisting of standard autografting nonmyeloablative radiotherapy and allografting. Patients without HLA-identical siblings are treated with standard double autologous transplantation as per Institutional guidelines or enrolled in other treatment programs approved by local IRBs.This is a multi-center study. The Division of Hematology of University of Torino at the S.G.B. Hospital, Torino, Italy, is the co-ordinating Center.

Unknown status19 enrollment criteria

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma...

MyelomaVenous Thromboembolism

To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day

Unknown status30 enrollment criteria

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies...

Non Hodgkin LymphomaHodgkin Lymphoma2 more

The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.

Unknown status20 enrollment criteria

Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma

Multiple Myeloma

The protocol aims at reducing transplant toxicity and mortality in patients with multiple myeloma.

Unknown status15 enrollment criteria

TCD Followed by autoSCT for Newly Diagnosed MM Patients

Multiple Myeloma

Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by high dose chemotherapy with autologous stem cell transplantation and TD maintenance therapy for the patients with newly diagnosed multiple myeloma.

Unknown status2 enrollment criteria

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Multiple Myeloma

Lytic bone disease continues to be one of the most devastating complications of multiple myeloma (MM) despite recent and dramatic advancements in MM management, and bone lesions persist and can continue to significantly impact a patient's morbidity, even when an individual's myeloma is otherwise under good control. To date, no agent has been shown to have a prolonged bone anabolic response in myeloma. Preliminary studies treating healthy postmenopausal women with a single dose of sotatercept demonstrated a rapid and sustained increase in serum biochemical markers of bone formation and a decrease in markers of bone resorption. Similarly, the murine analog to sotatercept, RAP-011, increases bone mineral density and strength in murine studies of both normal animals and models of bone loss. We hypothesize that sotatercept will provide an anabolic response for bone in myeloma patients with bone disease.

Withdrawn31 enrollment criteria

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer...

Myeloproliferative DisordersLeukemia6 more

RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and vomiting caused by opioids. It is not yet known whether aprepitant is more effective than ondansetron in treating nausea and vomiting caused by opioids in patients with cancer. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.

Withdrawn23 enrollment criteria
1...288289290...317

Need Help? Contact our team!


We'll reach out to this number within 24 hrs